Company intelligence / Profile preview

Freedom For All Diagnostics

Jericho, New York, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Freedom For All Diagnostics develops and distributes rapid diagnostic test kits for detecting both active and prior SARS-CoV-2 infections. Their pipeline includes rapid antibody, antigen, and spit-cup tests using chromatographic immunoassay technology. The company’s products are designed to be easy to use, accurate, and require no specialized equipment. These tests provide results within 15 minutes and are intended for broad screening applications in business, travel, education, healthcare settings, and public events.

Therapeutic areas: Infectious Diseases
Modalities: DeviceChromatographic immunoassay
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Freedom For All Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freedom For All Diagnostics.

Explore the full profile